Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

A significant proportion of patients experience delays in the diagnosis of heart failure due to
the non‐specific signs and symptoms of the syndrome. Diagnostic tools such as …

Aim Patients with heart failure (HF) often suffer from a range of comorbidities, which may
affect their health status. The aim of this study was to assess the impact of different …

Despite the availability of established treatments, heart failure (HF) is associated with a poor
prognosis and its management is suboptimal, highlighting the need for new options for …

Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly
reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse …

Background Little is known about the impact of chronic obstructive pulmonary disease
(COPD) in patients with heart failure with preserved ejection fraction (HFpEF). Methods and …

Abstract Dapagliflozin [Farxiga®(USA); Forxiga®(EU)], a sodium–glucose cotransporter 2
(SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults …

Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more
recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in …

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are common causes
of breathlessness which frequently co-exist; one potentially exacerbating the other …